Ablatus awarded £1M Innovate UK grant
We are delighted to have been awarded over £1M by the UK government to develop our novel minimally invasive treatment for soft tissue tumours. The award will fund a 2-year project to develop the protype device into a final version for use in patients for the first time. Partnering with Cambridge-based product engineering and design specialists eg technology, and Addenbrooke’s hospital, the grant will enable us to push forward with gathering essential clinical data needed for CE mark and commercial launch.
The device uses Bimodal Electric Tissue Ablation (BETA), an energy-based alternative to open surgery that offers a novel, cost-effective and efficient approach to destroying abnormal tissue, such as tumours, in situ and without major surgery.
Commenting on the award for Ablatus, Chief Medical Officer and Interim CEO Dr Natalie Hayes said “this is an enormous opportunity for Ablatus to build on the important work we have already done to complete development of what could be a game-changing treatment for patients with tumours. We are especially pleased to be able to bring this exciting new technology to local patients here in Cambridge when we start our first clinical study in Addenbrooke’s Hospital.”
Ablatus Chairman Dr Bill Allan said “this second Innovate UK award for Ablatus emphasises the significance of this technology in improving outcomes for large numbers of patients and is a fantastic endorsement of the promise that BETA technology has for these groups.”
Ablatus is backed by Mercia Asset Management PLC through the Northern VCT Funds.